Pursuant to the Market Abuse Regulation article 19, Gubra A/S, CVR no. 30514041 (the "Company”) hereby notifies receipt of information of the following transactions made by persons discharging managerial responsibilities in the Company and persons closely associated with them in…
Today, Gubra releases its results for the first quarter of 2026, building on a record year in 2025. In the quarter, we advanced our Biotech business, not least shown by strong results and progress for our partnered clinical-stage obesity programs…
Gubra today notes that its partner Boehringer Ingelheim plans to initiate Phase 2 clinical development in mid‑2026 of BI 3034701, an investigational, potential first‑in‑class triple GLP‑1, GIP and NPY2 receptor agonist peptide being developed for the treatment of obesity and…
On Thursday, 26 March 2026 at 10:00 am (CET), the annual general meeting of Gubra A/S (the "Company") was held at the Company's registered address Hørsholm Kongevej 11B, DK-2970 Hørsholm, with the following agenda: 1. The board of directors’ report…
Gubra’s partner AbbVie today announced positive topline results from the 12 and 13-weeks Phase 1 Multiple Ascending Dose (MAD) trial showing that ABBV-295 was well tolerated with a dose-dependent significant and clinically meaningful weight loss, compared to placebo. ABBV-295 treatment…
NOTICE TO CONVENE ANNUAL GENERAL MEETING 2026 GUBRA A/S CVR NO. 30 51 40 41 To the shareholders of Gubra A/S (CVR no. 30 51 40 41), notice is hereby given of the annual general meeting of Gubra A/S (the…
Pursuant to the Market Abuse Regulation article 19, Gubra A/S, CVR no. 30514041 (the "Company”) hereby notifies receipt of information of the following transactions made by persons discharging managerial responsibilities in the Company and persons closely associated with them in…
Today, Gubra releases its Annual Report for 2025 showing the strongest financial results in Gubra’s history. Group revenue and operating profit amounted to DKK 2.6 billion and DKK 2.2 billion, respectively. Several operational advancements were made across the company in…
A record year. Gubra’s Annual Report for 2025 marks a record-breaking year, with group revenue reaching DKK 2.6 billion and operating profit at DKK 2.2 billion. We have achieved significant milestones in our R&D pipeline, highlighted by the ABBV295 deal…
Gubra today announces that a clinical trial application (CTA) for the first-in-human study of GUB-UCN2, the company’s lead asset for high quality weight loss, has been submitted to the Competent Authority and associated Ethics Committee in Germany. The ambitious trial…